25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Akari Therapeutics PLC
Buy, Hold or Sell?

Let's analyze Akari Therapeutics PLC together

I guess you are interested in Akari Therapeutics PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Akari Therapeutics PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Akari Therapeutics PLC

I send you an email if I find something interesting about Akari Therapeutics PLC.

1. Quick Overview

1.1. Quick analysis of Akari Therapeutics PLC (30 sec.)










1.2. What can you expect buying and holding a share of Akari Therapeutics PLC? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.30
Expected worth in 1 year
$-0.84
How sure are you?
46.2%

+ What do you gain per year?

Total Gains per Share
$-0.53
Return On Investment
-22.0%

For what price can you sell your share?

Current Price per Share
$2.43
Expected price per share
$1.1701 - $3.7
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Akari Therapeutics PLC (5 min.)




Live pricePrice per Share (EOD)
$2.43
Intrinsic Value Per Share
$-18.66 - $-22.15
Total Value Per Share
$-18.97 - $-22.45

2.2. Growth of Akari Therapeutics PLC (5 min.)




Is Akari Therapeutics PLC growing?

Current yearPrevious yearGrowGrow %
How rich?-$3.7m$2.2m-$4.2m-218.5%

How much money is Akari Therapeutics PLC making?

Current yearPrevious yearGrowGrow %
Making money-$5m-$2.2m-$2.8m-55.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Akari Therapeutics PLC (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#858 / 959

Most Revenue
#899 / 959

Most Profit
#433 / 959

Most Efficient
#263 / 959
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Akari Therapeutics PLC?

Welcome investor! Akari Therapeutics PLC's management wants to use your money to grow the business. In return you get a share of Akari Therapeutics PLC.

First you should know what it really means to hold a share of Akari Therapeutics PLC. And how you can make/lose money.

Speculation

The Price per Share of Akari Therapeutics PLC is $2.4294. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Akari Therapeutics PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Akari Therapeutics PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.30. Based on the TTM, the Book Value Change Per Share is $-0.13 per quarter. Based on the YOY, the Book Value Change Per Share is $0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Akari Therapeutics PLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.62-25.6%-0.41-17.1%-0.12-5.1%-0.25-10.3%-0.42-17.1%
Usd Book Value Change Per Share-0.01-0.5%-0.13-5.5%0.020.9%-0.01-0.5%-0.01-0.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.5%-0.13-5.5%0.020.9%-0.01-0.5%-0.01-0.3%
Usd Price Per Share2.70-2.91-0.36-1.67-4.12-
Price to Earnings Ratio-1.08--2.06--0.73--2.08--2.07-
Price-to-Total Gains Ratio-218.60--80.45-44.94--3.33-6.18-
Price to Book Ratio-8.86--97.54-2.25--12.98--5.27-
Price-to-Total Gains Ratio-218.60--80.45-44.94--3.33-6.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.4294
Number of shares411
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.13-0.01
Usd Total Gains Per Share-0.13-0.01
Gains per Quarter (411 shares)-54.86-4.51
Gains per Year (411 shares)-219.45-18.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-219-2290-18-28
20-439-4480-36-46
30-658-6670-54-64
40-878-8860-72-82
50-1097-11050-90-100
60-1317-13240-108-118
70-1536-15430-126-136
80-1756-17620-144-154
90-1975-19810-162-172
100-2194-22000-180-190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%4.035.00.010.3%4.035.00.010.3%
Book Value Change Per Share0.03.01.00.0%4.05.03.033.3%9.08.03.045.0%18.018.03.046.2%18.018.03.046.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.039.00.0%0.00.039.00.0%
Total Gains per Share0.03.01.00.0%4.05.03.033.3%9.08.03.045.0%18.018.03.046.2%18.018.03.046.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Akari Therapeutics PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.012-0.133+981%0.022-156%-0.011-11%-0.008-37%
Book Value Per Share---0.305-0.159-48%0.188-262%0.147-308%0.911-133%
Current Ratio--0.5780.728-21%1.338-57%1.773-67%2.556-77%
Debt To Asset Ratio--1.7301.529+13%0.762+127%0.777+122%0.588+194%
Debt To Equity Ratio----0%4.302-100%1.828-100%1.209-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.622-0.414-33%-0.123-80%-0.250-60%-0.416-33%
Free Cash Flow Per Share---0.403-0.184-54%-0.298-26%-0.245-39%-0.324-20%
Free Cash Flow To Equity Per Share--0.2360.007+3319%-0.159+167%0.014+1557%0.134+77%
Gross Profit Margin--1.0001.166-14%0.971+3%1.027-3%1.014-1%
Intrinsic Value_10Y_max---22.149--------
Intrinsic Value_10Y_min---18.663--------
Intrinsic Value_1Y_max---0.980--------
Intrinsic Value_1Y_min---0.962--------
Intrinsic Value_3Y_max---3.890--------
Intrinsic Value_3Y_min---3.694--------
Intrinsic Value_5Y_max---7.938--------
Intrinsic Value_5Y_min---7.286--------
Market Cap29504091.240-11%32790420.00035325605.250-7%4407275.340+644%34824960.271-6%58210271.310-44%
Net Profit Margin----0%-0%-0%-2.2160%
Operating Margin----0%-0%-0%-2.3590%
Operating Ratio----0%-0%-0%2.354-100%
Pb Ratio-7.968+10%-8.855-97.544+1002%2.248-494%-12.979+47%-5.268-41%
Pe Ratio-0.976+10%-1.085-2.057+90%-0.735-32%-2.078+92%-2.072+91%
Price Per Share2.429-11%2.7002.909-7%0.363+644%1.673+61%4.123-35%
Price To Free Cash Flow Ratio-1.507+10%-1.675-1565.703+93373%-211.919+12552%-357.572+21247%-184.379+10908%
Price To Total Gains Ratio-196.694+10%-218.603-80.451-63%44.935-586%-3.331-98%6.178-3638%
Quick Ratio--0.4760.590-19%1.236-62%1.402-66%2.521-81%
Return On Assets---1.489-1.277-14%-0.187-87%-0.556-63%-0.441-70%
Return On Equity----0%-1.1420%-0.9300%-0.7090%
Total Gains Per Share---0.012-0.133+981%0.022-156%-0.011-11%-0.008-37%
Usd Book Value---3703000.000-1928500.000-48%2286228.500-262%3630675.950-202%12199226.308-130%
Usd Book Value Change Per Share---0.012-0.133+981%0.022-156%-0.011-11%-0.008-37%
Usd Book Value Per Share---0.305-0.159-48%0.188-262%0.147-308%0.911-133%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.622-0.414-33%-0.123-80%-0.250-60%-0.416-33%
Usd Free Cash Flow---4894000.000-2236214.325-54%-3614175.415-26%-4059829.198-17%-4595396.295-6%
Usd Free Cash Flow Per Share---0.403-0.184-54%-0.298-26%-0.245-39%-0.324-20%
Usd Free Cash Flow To Equity Per Share--0.2360.007+3319%-0.159+167%0.014+1557%0.134+77%
Usd Market Cap29504091.240-11%32790420.00035325605.250-7%4407275.340+644%34824960.271-6%58210271.310-44%
Usd Price Per Share2.429-11%2.7002.909-7%0.363+644%1.673+61%4.123-35%
Usd Profit---7558000.000-5033348.000-33%-2222559.000-71%-4222657.500-44%-5324283.590-30%
Usd Revenue----0%-0%-0%2615.385-100%
Usd Total Gains Per Share---0.012-0.133+981%0.022-156%-0.011-11%-0.008-37%
 EOD+2 -6MRQTTM+7 -21YOY+9 -205Y+4 -2510Y+6 -25

3.3 Fundamental Score

Let's check the fundamental score of Akari Therapeutics PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.976
Price to Book Ratio (EOD)Between0-1-7.968
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.476
Current Ratio (MRQ)Greater than10.578
Debt to Asset Ratio (MRQ)Less than11.730
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.489
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Akari Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.910
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Akari Therapeutics PLC

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-10-24 06:47:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Akari Therapeutics PLC earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Akari Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-221.6%+221.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--135.5%+135.5%
TTM--205.3%+205.3%
YOY--207.5%+207.5%
5Y--353.5%+353.5%
10Y-221.6%-464.5%+242.9%
4.3.1.2. Return on Assets

Shows how efficient Akari Therapeutics PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • -148.9% Return on Assets means that Akari Therapeutics PLC generated $-1.49 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Akari Therapeutics PLC:

  • The MRQ is -148.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -127.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-148.9%TTM-127.7%-21.2%
TTM-127.7%YOY-18.7%-109.0%
TTM-127.7%5Y-55.6%-72.1%
5Y-55.6%10Y-44.1%-11.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-148.9%-10.9%-138.0%
TTM-127.7%-11.8%-115.9%
YOY-18.7%-11.1%-7.6%
5Y-55.6%-12.7%-42.9%
10Y-44.1%-14.3%-29.8%
4.3.1.3. Return on Equity

Shows how efficient Akari Therapeutics PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • 0.0% Return on Equity means Akari Therapeutics PLC generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Akari Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-114.2%+114.2%
TTM-5Y-93.0%+93.0%
5Y-93.0%10Y-70.9%-22.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.7%+13.7%
TTM--16.0%+16.0%
YOY-114.2%-13.5%-100.7%
5Y-93.0%-18.5%-74.5%
10Y-70.9%-19.0%-51.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Akari Therapeutics PLC.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Akari Therapeutics PLC is operating .

  • Measures how much profit Akari Therapeutics PLC makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Akari Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-235.9%+235.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.0%+286.0%
TTM--313.4%+313.4%
YOY--222.8%+222.8%
5Y--385.5%+385.5%
10Y-235.9%-494.6%+258.7%
4.3.2.2. Operating Ratio

Measures how efficient Akari Therapeutics PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y2.354-2.354
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.842-2.842
TTM-3.179-3.179
YOY-3.300-3.300
5Y-4.823-4.823
10Y2.3546.520-4.166
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Akari Therapeutics PLC.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Akari Therapeutics PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.58 means the company has $0.58 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 0.578. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.728. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.578TTM0.728-0.149
TTM0.728YOY1.338-0.610
TTM0.7285Y1.773-1.045
5Y1.77310Y2.556-0.784
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5783.747-3.169
TTM0.7283.923-3.195
YOY1.3384.715-3.377
5Y1.7735.960-4.187
10Y2.5566.291-3.735
4.4.3.2. Quick Ratio

Measures if Akari Therapeutics PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A Quick Ratio of 0.48 means the company can pay off $0.48 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 0.476. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.590. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.476TTM0.590-0.114
TTM0.590YOY1.236-0.646
TTM0.5905Y1.402-0.812
5Y1.40210Y2.521-1.119
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4763.342-2.866
TTM0.5903.522-2.932
YOY1.2364.658-3.422
5Y1.4025.922-4.520
10Y2.5216.478-3.957
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Akari Therapeutics PLC.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Akari Therapeutics PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Akari Therapeutics PLC to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.73 means that Akari Therapeutics PLC assets are financed with 173.0% credit (debt) and the remaining percentage (100% - 173.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 1.730. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.529. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.730TTM1.529+0.200
TTM1.529YOY0.762+0.767
TTM1.5295Y0.777+0.752
5Y0.77710Y0.588+0.189
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7300.338+1.392
TTM1.5290.346+1.183
YOY0.7620.308+0.454
5Y0.7770.365+0.412
10Y0.5880.379+0.209
4.5.4.2. Debt to Equity Ratio

Measures if Akari Therapeutics PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY4.302-4.302
TTM-5Y1.828-1.828
5Y1.82810Y1.209+0.619
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.392-0.392
TTM-0.439-0.439
YOY4.3020.375+3.927
5Y1.8280.450+1.378
10Y1.2090.488+0.721
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Akari Therapeutics PLC generates.

  • Above 15 is considered overpriced but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A PE ratio of -1.08 means the investor is paying $-1.08 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Akari Therapeutics PLC:

  • The EOD is -0.976. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.085. Based on the earnings, the company is expensive. -2
  • The TTM is -2.057. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.976MRQ-1.085+0.109
MRQ-1.085TTM-2.057+0.972
TTM-2.057YOY-0.735-1.322
TTM-2.0575Y-2.078+0.022
5Y-2.07810Y-2.072-0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.976-2.326+1.350
MRQ-1.085-2.468+1.383
TTM-2.057-2.987+0.930
YOY-0.735-3.444+2.709
5Y-2.078-5.905+3.827
10Y-2.072-6.278+4.206
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Akari Therapeutics PLC:

  • The EOD is -1.507. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.675. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1,565.703. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.507MRQ-1.675+0.168
MRQ-1.675TTM-1,565.703+1,564.028
TTM-1,565.703YOY-211.919-1,353.785
TTM-1,565.7035Y-357.572-1,208.131
5Y-357.57210Y-184.379-173.193
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.507-3.181+1.674
MRQ-1.675-3.267+1.592
TTM-1,565.703-3.527-1,562.176
YOY-211.919-4.590-207.329
5Y-357.572-8.076-349.496
10Y-184.379-8.938-175.441
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Akari Therapeutics PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -8.86 means the investor is paying $-8.86 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Akari Therapeutics PLC:

  • The EOD is -7.968. Based on the equity, the company is expensive. -2
  • The MRQ is -8.855. Based on the equity, the company is expensive. -2
  • The TTM is -97.544. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.968MRQ-8.855+0.887
MRQ-8.855TTM-97.544+88.689
TTM-97.544YOY2.248-99.792
TTM-97.5445Y-12.979-84.564
5Y-12.97910Y-5.268-7.711
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.9681.931-9.899
MRQ-8.8551.982-10.837
TTM-97.5442.197-99.741
YOY2.2482.400-0.152
5Y-12.9793.585-16.564
10Y-5.2684.208-9.476
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Akari Therapeutics PLC.

4.8.1. Institutions holding Akari Therapeutics PLC

Institutions are holding 1.484% of the shares of Akari Therapeutics PLC.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Omnia Family Wealth, LLC0.72150.10028762800
2024-06-30HPM Partners LLC0.19470.00022364300
2024-06-30Cresset Asset Management, LLC0.15160.000218408184080
2024-06-30Susquehanna International Group, LLP0.1418017226172260
2024-06-30Renaissance Technologies Corp0.14050.000117069230015.5732
2024-06-30UBS Group AG0.1314015953159530
2024-06-30Bank of America Corp0.0012015000
2024-06-30Advisor Group Holdings, Inc.0.000801001000
2024-06-30Morgan Stanley - Brokerage Accounts006-6-50
2024-06-30Cornerstone Planning Group LLC00500
2024-06-30Sabby Management LLC000-48491-100
2024-03-31Tower Research Capital LLC000-7-100
2024-06-30Truvestments Capital LLC000-50-100
Total 1.48350.1007180188+5433+3.0%

4.9.2. Funds holding Akari Therapeutics PLC

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30LUX IM Global Medtech HX0.11130.02041351400
2024-08-31Fidelity Nasdaq Composite Index0.01240151200
Total 0.12370.02041502600.0%

5.3. Insider Transactions

Insiders are holding 37.613% of the shares of Akari Therapeutics PLC.

DateOwnerTypeAmountPricePost Transaction AmountLink
2015-09-18Mark S CohenBUY10556000.191055600
2014-04-15Sabby Management, LlcBUY201005.03
2014-04-11Sabby Management, LlcBUY25755.35
2014-04-08Sabby Management, LlcBUY684045.59
2014-04-02Sabby Management, LlcBUY282076.22
2014-03-27Sabby Management, LlcBUY162036.66
2014-03-24Sabby Management, LlcBUY111006.83
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Total Other Income Expense Net 6,146-5,8532940294129423-2,426-2,003



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets5,076
Total Liabilities8,779
Total Stockholder Equity-3,703
 As reported
Total Liabilities 8,779
Total Stockholder Equity+ -3,703
Total Assets = 5,076

Assets

Total Assets5,076
Total Current Assets5,076
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 4,177
Other Current Assets 899
Total Current Assets  (as reported)5,076
Total Current Assets  (calculated)5,076
+/- 0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,779
Long-term Liabilities0
Total Stockholder Equity-3,703
Total Current Liabilities
Short-term Debt 1,000
Short Long Term Debt 1,000
Accounts payable 4,686
Other Current Liabilities 8,779
Total Current Liabilities  (as reported)8,779
Total Current Liabilities  (calculated)15,465
+/- 6,686
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock2,430
Retained Earnings -240,585
Accumulated Other Comprehensive Income 51,445
Other Stockholders Equity 183,007
Total Stockholder Equity (as reported)-3,703
Total Stockholder Equity (calculated)-3,703
+/-0
Other
Capital Stock2,430
Cash and Short Term Investments 4,177
Common Stock Shares Outstanding 9,418
Current Deferred Revenue-5,686
Liabilities and Stockholders Equity 5,076
Net Debt -3,177
Net Invested Capital -2,703
Net Working Capital -3,703
Short Long Term Debt Total 1,000



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-31
> Total Assets 
0
0
0
6,480
4,317
2,960
79,174
69,894
62,959
57,633
52,070
45,874
36,517
32,053
22,427
25,496
25,496
29,050
12,627
16,452
16,452
5,151
10,670
10,307
9,969
14,452
13,694
14,605
7,840
4,830
14,719
11,648
19,455
11,371
13,832
13,832
8,013
8,013
4,355
4,355
2,772
5,076
5,0762,7724,3554,3558,0138,01313,83213,83211,37119,45511,64814,7194,8307,84014,60513,69414,4529,96910,30710,6705,15116,45216,45212,62729,05025,49625,49622,42732,05336,51745,87452,07057,63362,95969,89479,1742,9604,3176,480000
   > Total Current Assets 
1
0
0
6,431
4,273
2,920
78,939
69,658
62,693
57,374
51,824
45,634
36,282
31,805
22,194
25,266
25,266
28,813
12,041
16,399
16,399
5,091
10,632
10,272
9,939
14,426
13,667
14,578
7,813
4,804
14,695
11,625
19,433
11,352
13,815
13,815
7,997
7,997
4,341
4,341
2,772
5,076
5,0762,7724,3414,3417,9977,99713,81513,81511,35219,43311,62514,6954,8047,81314,57813,66714,4269,93910,27210,6325,09116,39916,39912,04128,81325,26625,26622,19431,80536,28245,63451,82457,37462,69369,65878,9392,9204,2736,431001
       Cash And Cash Equivalents 
-1
0
0
6,216
4,016
2,718
78,773
68,920
61,430
9,662
5,525
34,099
24,919
30,119
20,974
23,781
23,781
28,107
10,073
5,968
5,968
2,737
6,269
5,732
7,822
12,746
12,318
14,056
6,668
3,792
13,391
9,361
16,723
8,151
13,250
13,250
7,181
7,181
3,845
3,845
1,310
4,177
4,1771,3103,8453,8457,1817,18113,25013,2508,15116,7239,36113,3913,7926,66814,05612,31812,7467,8225,7326,2692,7375,9685,96810,07328,10723,78123,78120,97430,11924,91934,0995,5259,66261,43068,92078,7732,7184,0166,21600-1
       Short-term Investments 
1
0
0
0
7
0
0
0
0
46,120
45,101
10,022
10,022
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000010,02210,02245,10146,120000070001
       Net Receivables 
0
0
0
73
115
60
10
10
11
11
11
0
0
0
0
0
0
0
0
10,431
10,431
0
2,903
4,540
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000004,5402,903010,43110,4310000000011111110106011573000
       Other Current Assets 
0
0
0
0
130
0
0
1
1
2
1
2
1
2
1
1
1,490
1
1,967
2,008
2
2,354
4
1
2
2
1
0
1,145
1,012
1,304
90
326
115
565
565
817
187
496
496
1,462
899
8991,462496496187817565565115326901,3041,0121,1450122142,35422,0081,96711,490112121211001300000
   > Long-term Assets 
-1
0
0
49
44
40
235
235
266
259
246
240
235
248
233
229
229
237
586
53
53
60
38
35
30
26
27
27
26
26
24
23
21
19
17
17
16
16
14
14
0
0
0014141616171719212324262627272630353860535358623722922923324823524024625926623523540444900-1
       Property Plant Equipment 
0
0
0
49
44
40
35
41
75
71
62
58
54
74
65
47
47
56
30
20
20
12
8
5
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000025812202030564747657454586271754135404449000
       Intangible Assets 
0
0
0
0
0
0
58
52
49
46
43
39
39
32
26
40
40
39
35
33
33
31
29
30
28
26
27
27
26
26
24
23
21
19
17
17
16
16
14
14
0
0
0014141616171719212324262627272628302931333335394040263239394346495258000000
       Long-term Assets Other 
-1
0
0
0
10
0
142
142
142
142
142
142
142
142
142
142
142
142
522
522
148
17
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000017148522522142142142142142142142142142142142142010000-1
> Total Liabilities 
0
0
0
1,627
1,722
1,987
37,843
21,174
16,601
17,049
11,030
11,771
14,121
9,201
9,385
9,171
9,171
9,071
6,324
3,076
3,076
6,523
7,419
6,471
8,153
11,113
8,835
5,220
3,903
3,242
3,356
6,093
5,524
3,045
12,041
12,041
5,232
5,232
4,584
4,584
6,325
8,779
8,7796,3254,5844,5845,2325,23212,04112,0413,0455,5246,0933,3563,2423,9035,2208,83511,1138,1536,4717,4196,5233,0763,0766,3249,0719,1719,1719,3859,20114,12111,77111,03017,04916,60121,17437,8431,9871,7221,627000
   > Total Current Liabilities 
0
0
0
1,359
910
960
37,797
21,125
16,549
16,994
10,975
11,715
14,064
9,143
9,332
9,077
9,077
9,023
6,149
3,076
3,076
6,523
7,419
5,456
8,153
11,113
8,835
5,220
3,903
3,242
3,356
6,093
5,524
3,045
12,041
12,041
5,232
5,232
4,584
4,584
6,325
8,779
8,7796,3254,5844,5845,2325,23212,04112,0413,0455,5246,0933,3563,2423,9035,2208,83511,1138,1535,4567,4196,5233,0763,0766,1499,0239,0779,0779,3329,14314,06411,71510,97516,99416,54921,12537,7979609101,359000
       Short-term Debt 
0
0
0
1
0
0
3,031
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
1,00000000000000000000000000000000000003,031001000
       Short Long Term Debt 
0
0
0
534
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
1,0000000000000000000000000000000000000000534000
       Accounts payable 
0
0
0
1,007
296
629
3,754
4,321
625
1,918
1,308
2,214
924
2,842
1,943
2,384
2,384
1,971
1,404
1,586
1,586
1,482
1,315
1,228
966
2,191
2,411
3,381
2,832
1,685
1,923
1,789
3,076
1,635
947
947
1,031
1,031
1,671
1,671
3
4,686
4,68631,6711,6711,0311,0319479471,6353,0761,7891,9231,6852,8323,3812,4112,1919661,2281,3151,4821,5861,5861,4041,9712,3842,3841,9432,8429242,2141,3081,9186254,3213,7546292961,007000
       Other Current Liabilities 
0
0
0
351
614
331
27,166
16,804
15,924
15,076
9,667
9,500
13,139
6,301
7,389
6,693
6,693
7,052
4,745
1,490
1,490
5,042
6,104
4,228
7,187
8,922
6,425
0
1,071
1,556
1,432
4,305
2,448
1,411
11,094
11,094
4,201
4,201
2,913
2,913
6,322
8,779
8,7796,3222,9132,9134,2014,20111,09411,0941,4112,4484,3051,4321,5561,07106,4258,9227,1874,2286,1045,0421,4901,4904,7457,0526,6936,6937,3896,30113,1399,5009,66715,07615,92416,80427,166331614351000
   > Long-term Liabilities 
0
0
0
268
812
1,027
46
49
52
55
56
56
57
58
53
94
94
48
175
0
0
0
0
1,015
0
0
0
0
0
1,685
1,789
1,789
3,076
1,635
0
0
0
0
0
0
0
0
000000001,6353,0761,7891,7891,685000001,01500001754894945358575656555249461,027812268000
       Other Liabilities 
0
0
0
49
0
1,027
46
49
52
55
55
56
57
58
53
48
94
213
175
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000017521394485358575655555249461,027049000
> Total Stockholder Equity
0
0
0
4,853
2,595
973
41,331
48,720
46,358
40,584
41,040
34,103
22,396
22,852
13,042
16,324
16,324
19,979
6,303
13,376
13,376
-1,372
3,250
3,836
1,816
3,339
4,858
9,384
3,937
1,588
11,363
5,555
13,931
8,326
1,791
1,791
2,781
2,781
-229
-229
-3,553
-3,703
-3,703-3,553-229-2292,7812,7811,7911,7918,32613,9315,55511,3631,5883,9379,3844,8583,3391,8163,8363,250-1,37213,37613,3766,30319,97916,32416,32413,04222,85222,39634,10341,04040,58446,35848,72041,3319732,5954,853000
   Common Stock
0
0
0
927
927
927
18,341
18,341
18,341
18,341
18,341
18,341
18,341
18,341
18,341
22,928
22,928
22,928
23,651
23,651
23,651
24,538
30,124
31,987
40,086
46,579
46,579
385
385
396
476
476
593
593
745
745
1,012
1,012
1,324
1,324
1,598
2,430
2,4301,5981,3241,3241,0121,01274574559359347647639638538546,57946,57940,08631,98730,12424,53823,65123,65123,65122,92822,92822,92818,34118,34118,34118,34118,34118,34118,34118,34118,341927927927000
   Retained Earnings Total Equity000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
2
0
197
156
-36
-192
-341
-280
-325
-374
-288
-203
-203
-236
-296
-12,246
-12,246
-405
-402
-12,242
-572
-618
-621
-648
-342
-420
-447
-541
-573
-622
51,423
51,423
51,368
-826
51,154
51,154
51,433
51,445
51,44551,43351,15451,154-82651,36851,42351,423-622-573-541-447-420-342-648-621-618-572-12,242-402-405-12,246-12,246-296-236-203-203-288-374-325-280-341-192-36156197020000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
106,239
106,616
107,097
107,961
109,560
110,499
109,596
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000109,596110,499109,560107,961107,097106,616106,239000000000000000000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
34,116
34,173
34,224
86,062
87,019
87,836
88,668
89,692
90,979
91,902
92,727
93,208
105,276
105,278
104,800
106,239
106,616
118,443
107,961
109,560
122,327
109,596
112,989
113,070
191,445
192,013
194,077
205,251
205,325
218,792
218,915
167,076
167,076
170,852
223,047
174,754
174,754
176,443
183,007
183,007176,443174,754174,754223,047170,852167,076167,076218,915218,792205,325205,251194,077192,013191,445113,070112,989109,596122,327109,560107,961118,443106,616106,239104,800105,278105,27693,20892,72791,90290,97989,69288,66887,83687,01986,06234,22434,17334,116000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

All numbers in thousands.




5.6. Income Statements

All numbers in thousands.